Skip to main content

Table 2 Univariate Cox and logistic regression analyses to predict distant recurrence-free survival using the dichotomized and continuous expression data of HLA-A, HLA-B, and HLA-C, respectively. HLA-A, but not HLA-B and HLA-C, is predictive for patient survival, but not for response to neoadjuvant treatment

From: Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Univariate Cox regression—distant recurrence-free survival (MDACC)
  HR95% CIP
 HLA-AHigh vs. low2.4931.131–5.4940.023
 HLA-BHigh vs. low2.0420.956–4.3580.065
 HLA-CHigh vs. low1.4770.723–3.0160.284
Univariate logistic regression—pCR (MDACC)
  HR95% CIP
 HLA-AHigh vs. low1.7220.699–4.2890.234
 HLA-BHigh vs. low1.3730.552–3.3830.487
 HLA-CHigh vs. low1.3730.552–3.3830.487
Univariate Cox regression—distant recurrence-free survival (MDACC)
  HR95% CIP
 HLA-AContinuous1.5761.079–2.3030.019
 HLA-BContinuous1.3640.973–1.9120.072
 HLA-CContinuous1.3590.941–1.9650.102
Univariate logistic regression—pCR (MDACC)
  HR95% CIP
 HLA-AContinuous1.3460.857–2.1030.192
 HLA-BContinuous1.3670.887–2.1320.160
 HLA-CContinuous1.5190.948–2.4660.085